11 Bioanalytical Lab Providers Operating in Europe in 2026

Bioanalytical laboratories measure drug, metabolite, and biomarker concentrations in biological samples — blood, plasma, urine, tissue — generating the pharmacokinetic and pharmacodynamic data Sponsors rely on to understand how a compound behaves in the body. This kind of bioanalytical testing service underpins everything from early discovery screening through the bioequivalence studies required for regulatory filings, and Sponsors running trials across Europe often look for a CRO bioanalytical laboratory with a genuinely regional presence, both for local regulatory relationships and to keep sample logistics manageable.

The bioanalytical lab providers below, drawn from the UK, Germany, Belgium, Spain, Sweden, Switzerland, and the Czech Republic, are listed in no particular order. Between them, these companies and providers work across LC-MS/MS, ligand-binding assays, immunogenicity testing, flow cytometry, and specialized bioanalysis for gene and cell therapy vectors, spanning routine bioequivalence work through advanced ADC and viral vector bioanalysis.

Alderley Analytical

In October 2024, Alderley Analytical was acquired by Synexa Life Sciences, a specialist biomarker and bioanalysis provider, extending Synexa's bioanalytical footprint into the UK. Based at Alderley Park in Macclesfield, the company specializes in mass spectrometry and ligand-binding assays across small molecules, large molecules, peptides, oligonucleotides, and biomarkers. Founded in 2014, Alderley Analytical operates as a GLP/GCP-compliant laboratory supporting projects from discovery through late-stage clinical development. Its instrumentation includes Waters and Sciex mass spectrometers alongside MSD and standard plate readers for immunoassay work.

Anapharm Bioanalytics

Anapharm Bioanalytics runs a GLP-certified, FDA-inspected, GCP-compliant, and ANVISA-certified bioanalytical laboratory in Barcelona, using LC-MS/MS and ligand-binding assay (LBA) platforms to support pharmacokinetic, biomarker, and immunogenicity testing. Founded in 2003, the company has since undergone more than 20 regulatory inspections from the FDA, several EU health authorities, and Brazil's ANVISA. Its services span bioequivalence studies and full-service outsourcing for preclinical work through Phase I–IV clinical trials. Anapharm operates a 1,500 m² laboratory facility with controlled access, serving the pharmaceutical, biopharmaceutical, and generic drug industries worldwide.

BioNotus

BioNotus concentrates on bioanalysis for small and large molecules, drawing on LC-MS/MS and LC-UV/FLUO platforms alongside pharmacometric modeling — population PK, physiology-based PK, and PK/PD — with a stated specialization in monoclonal antibodies. The Belgian company, founded in 2017 by Johan Van Daele and Pieter Annaert, has passed a GLP inspection that allows it to conduct regulated bioanalytical studies. Based in Niel, near Antwerp, the lab pairs its core bioanalysis work with ADMET evaluation, proteomics, peptidomics, and metabolomics services. BioNotus is a small team by design, with a stated aim of offering fit-for-purpose bioanalytical solutions on shorter timelines.

Pronexus Analytical

Pronexus Analytical specializes in central nervous system pharmacology and metabolic disorders, running in vivo microdialysis alongside UHPLC-MS/MS and high-sensitivity HPLC to quantify neurotransmitters, metabolites, and drug levels in microliter volumes of plasma, CSF, and brain tissue extracts. Based in Bromma, Sweden, the company's bioanalytical laboratory and animal research facility both operate under GLP compliance with regulatory approvals in place. Pronexus was founded in 2007 and works with pharmaceutical and academic partners to evaluate drug actions and validate candidate compounds through in vivo, in vitro, and ex vivo techniques. Immunoassays round out its bioanalytical toolkit for detecting neuroactive molecules.

ProtaGene CGT

ProtaGene's bioanalytical work centers on gene and cell therapies, including vector integration site analysis, biodistribution studies, and vector shedding assessments — evaluations regulators recommend after administering AAV and other viral vector therapies. The Heidelberg, Germany-based company traces its bioanalytical lineage to a 2021 merger of Protagen Protein Services and GeneWerk's vector-safety capabilities, and now operates laboratories across Germany and the United States. It also applies LC-MS, qPCR, and RNA-Seq to quantify transgene expression in target tissues, supporting both preclinical safety packages and clinical-phase regulatory submissions. ProtaGene's services extend to broader biologic drug analytics and product characterization work for biopharmaceutical clients.

CEPHA

CEPHA operates a GLP-certified bioanalytical laboratory alongside a 36-bed clinical unit for pharmacokinetic and bioavailability/bioequivalence studies, plus a separate 6-bed Phase I unit, all housed at its Pilsen, Czech Republic headquarters. Founded in 1992, the company also maintains offices in Prague and Aesch, Switzerland. Its bioassay work supports study protocol writing, pharmacokinetic analysis, and statistical evaluation for drug and metabolite quantification in complex biological matrices. CEPHA describes itself as a full-service CRO, with capabilities spanning bioanalytical testing through regulatory affairs.

3S Pharma

3S Pharma runs an AI-assisted bioanalytical laboratory processing more than 100,000 samples annually across over 200 validated methods, using LC-MS/MS, ICP-MS, and ligand-binding techniques for small and large molecules including peptides, proteins, and monoclonal antibodies. Headquartered in Harpstedt, Germany since 1996, the company also operates clinical research units in Romania and Moldova that have passed inspections from the FDA and several European regulatory agencies. Its bioanalytical services support bioequivalence and bioavailability studies, pharmacokinetic profiling, and drug-drug interaction assessments. 3S Pharma pairs this lab work with clinical monitoring and auditing services across a study footprint spanning three continents.

Immundnz

Immundnz is a small, Alderley Park-based team combining expertise in immunology, biochemistry, and bio-analytical chemistry to build customized immune assays — including dendritic cell, T-cell, and cytokine-release assays — for preclinical drug research. Co-founded in 2016 by Dr. Masih Alam and Dr. Ir. Robert-Jan Lamers, the company has drawn UKRI and Horizon 2020 grant funding for biomarker and immune-response modeling projects, including work identifying biomarkers linked to COVID-19 severity. Its ex vivo and in vitro cell culture systems support biomarker analysis alongside its core bio-analytical chemistry offering. Immundnz has operated from a dedicated in vitro immunology laboratory at Alderley Park since 2017.

Solvias

Solvias runs a dedicated biological analysis division alongside its small-molecule and CMC analytical services, offering bioanalytical LC-MS/MS testing plus characterization of monoclonal antibodies, antibody-drug conjugates, and other biologics. Headquartered in Kaiseraugst, Switzerland, with additional sites in France, the Netherlands, and the United States, the company traces its origins to a 1999 management buyout and now operates six global facilities. Solvias supports cell and gene therapy programs through its Hombourg, France center of excellence, which focuses on cell-based bioassays, molecular biology, and microbiological testing. Its laboratories operate under ISO, GMP, GLP, and FDA-aligned standards.

Quinta-Analytica

Quinta-Analytica's bioanalytical department has completed more than 600 bio-studies for pharmaceutical clients across Europe, the United States, Asia, and Australia, with a stated laboratory capacity of up to 3,750 biological sample analyses per day using LC-MS/MS instrumentation. Founded in 1997 and based in the Czech Republic, the company pairs this bioanalytical work with in-house Phase I clinical units for bioequivalence and pharmacokinetic/pharmacodynamic studies. Quinta-Analytica has passed more than ten FDA audits spanning GMP, GLP, and GCP inspections, and holds certifications covering both human and veterinary medicines. A separate biopharmaceutical quality-control group within the company analyzes peptide and protein investigational products, including biosimilars.

Ardena

Ardena runs a bioanalytical CRO division spanning small- and large-molecule bioanalysis, immunogenicity testing, flow cytometry, qPCR, and integrated antibody-drug and other conjugate (ADC/XDC) bioanalysis, staffed by more than 90 specialists across facilities in the Netherlands and the United States. Headquartered in Ghent, Belgium, the company pairs this bioanalytical arm with contract development and manufacturing services, and in 2025 expanded its bioanalytical laboratory in Oss, Netherlands, with LC-MS/MS and Gyrolab automated ELISA platforms. Its Assen, Netherlands site serves as a bioanalytical center of excellence with added immunochemistry and flow cytometry capacity. Founded through a series of acquisitions beginning with PharmaVize, Ardena now operates across Belgium, the Netherlands, Spain, Sweden, and the United States.

Explore the full Bioanalytical Labs landscape

The companies above represent a portion of a much larger field.

Diligent's platform includes over 325 Bioanalytical Labs Vendors, many with Vendor qualification data available on demand. Book a demo to explore Diligent's full vendor discovery database.

This article is intended as an informational overview of vendors operating in this space. Inclusion on this list does not constitute an endorsement, recommendation, or qualification by Diligent.